PDF(Pubmed)
Abstract：
UNASSIGNED: Paediatric oncologists often encounter challenges when seeking compassionate access to off-label therapies for their patients. This study employed implementation science and co-design techniques to develop the ProCure medicines database, with the goal of streamlining the application process and addressing identified barriers in paediatric oncology.
UNASSIGNED: This study utilised an exploratory qualitative research design. Seventeen healthcare providers, including oncologists, nurse consultants, and allied health professionals, participated in semi-structured interviews guided by the Consolidated Framework for Implementation Research (CFIR) and a visual process map aid. Deductive qualitative data analysis, according to the CFIR constructs, identified key barriers and facilitators. Collaborative design sessions engaged multidisciplinary teams to develop the ProCure beta version.
UNASSIGNED: Barriers to off-label therapy access included resource-intensive applications, time sensitive decision-making, and complex pharmaceutical information. Facilitators included Drug Access Navigators, Molecular Tumour Boards, and a multi-disciplinary approach. ProCure addressed end-user needs by centralising medicines information. Additional features suggested by healthcare providers included blood-brain-barrier penetrability data and successful application examples.
UNASSIGNED: ProCure represents a promising solution to the challenges paediatric oncologists face in accessing off-label therapies. By centralising information, it simplifies the application process, aids decision-making, and promotes a collaborative approach to patient care. The potential of the database to stream and enhance off-label therapy access underscores its relevance in improving paediatric oncology practise. Further research and implementation efforts are warranted to assess ProCure\'s real-world impact and refine its features based on user feedback.
UNASSIGNED: This study utilised an exploratory qualitative research design. Seventeen healthcare providers, including oncologists, nurse consultants, and allied health professionals, participated in semi-structured interviews guided by the Consolidated Framework for Implementation Research (CFIR) and a visual process map aid. Deductive qualitative data analysis, according to the CFIR constructs, identified key barriers and facilitators. Collaborative design sessions engaged multidisciplinary teams to develop the ProCure beta version.
UNASSIGNED: Barriers to off-label therapy access included resource-intensive applications, time sensitive decision-making, and complex pharmaceutical information. Facilitators included Drug Access Navigators, Molecular Tumour Boards, and a multi-disciplinary approach. ProCure addressed end-user needs by centralising medicines information. Additional features suggested by healthcare providers included blood-brain-barrier penetrability data and successful application examples.
UNASSIGNED: ProCure represents a promising solution to the challenges paediatric oncologists face in accessing off-label therapies. By centralising information, it simplifies the application process, aids decision-making, and promotes a collaborative approach to patient care. The potential of the database to stream and enhance off-label therapy access underscores its relevance in improving paediatric oncology practise. Further research and implementation efforts are warranted to assess ProCure\'s real-world impact and refine its features based on user feedback.
摘要：
儿科肿瘤学家在为患者寻求具有同情心的标签外疗法时经常遇到挑战。本研究采用实施科学和协同设计技术来开发ProCure药物数据库，目的是简化应用流程并解决儿科肿瘤学中已发现的障碍。
■本研究采用了探索性定性研究设计。17个医疗保健提供者，包括肿瘤学家,护士顾问,和专职医疗专业人员，参加了由实施研究综合框架（CFIR）和可视化过程图辅助指导的半结构化访谈。演绎定性数据分析，根据CFIR构造，确定了关键障碍和促进者。协作设计会议邀请多学科团队开发ProCurebeta版本。
■标签外治疗的障碍包括资源密集型应用，时间敏感决策，和复杂的药物信息。主持人包括药物进入导航员，分子肿瘤板，和多学科方法。ProCure通过集中药品信息来满足最终用户的需求。医疗保健提供者建议的其他功能包括血脑屏障穿透性数据和成功的应用示例。
ProCure代表了一种有希望的解决方案，以解决儿科肿瘤学家在获得标签外治疗方面面临的挑战。通过集中信息，它简化了申请过程，有助于决策，并促进患者护理的协作方法。数据库在流动和增强标签外治疗访问方面的潜力强调了其在改善儿科肿瘤学实践中的相关性。需要进一步的研究和实施工作来评估ProCure的现实世界影响，并根据用户反馈改进其功能。
■本研究采用了探索性定性研究设计。17个医疗保健提供者，包括肿瘤学家,护士顾问,和专职医疗专业人员，参加了由实施研究综合框架（CFIR）和可视化过程图辅助指导的半结构化访谈。演绎定性数据分析，根据CFIR构造，确定了关键障碍和促进者。协作设计会议邀请多学科团队开发ProCurebeta版本。
■标签外治疗的障碍包括资源密集型应用，时间敏感决策，和复杂的药物信息。主持人包括药物进入导航员，分子肿瘤板，和多学科方法。ProCure通过集中药品信息来满足最终用户的需求。医疗保健提供者建议的其他功能包括血脑屏障穿透性数据和成功的应用示例。
ProCure代表了一种有希望的解决方案，以解决儿科肿瘤学家在获得标签外治疗方面面临的挑战。通过集中信息，它简化了申请过程，有助于决策，并促进患者护理的协作方法。数据库在流动和增强标签外治疗访问方面的潜力强调了其在改善儿科肿瘤学实践中的相关性。需要进一步的研究和实施工作来评估ProCure的现实世界影响，并根据用户反馈改进其功能。
